Wound care providers who accept rebates, consulting fees, or free skin substitute product from a manufacturer or distributor are standing inside the highest-risk zone of current federal enforcement. In December 2025, the Department of Justice resolved a $309 million civil False Claims Act settlement against Arizona wound graft company owners who took kickbacks from a distributor for order volume. The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), does not require proof that the underlying wound care was medically unnecessary. A financial relationship built around referral volume can expose a practice to civil liability, criminal liability, and Medicare exclusion, all from the same set of facts.
What the Anti-Kickback Statute Reaches
The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving anything of value in exchange for referring or ordering items reimbursable by a federal health care program. Remuneration covers a rebate check, a consulting fee, a speaking honorarium, or a box of free product. The government must prove intent: that at least one purpose of the payment was to induce referrals. That intent requirement separates the AKS from the Stark Law, which imposes strict liability on a physician self-referral regardless of intent. A wound care practice defending an AKS allegation is defending against why the money moved, not only whether it moved.
Consulting Arrangements That Function as Disguised Remuneration
OIG's November 2020 Special Fraud Alert on speaker and consulting programs warned that when a physician is paid to consult or present on a manufacturer's behalf, the arrangement gets scrutinized for whether genuine work happened at all. OIG pointed to compensation that tracks referral or order volume rather than hours worked, venues with no educational purpose, and programs repeated for the same small audience with no new content each time. A wound care consulting arrangement that cannot produce a signature log, meeting notes, or any other record of work actually performed reads, on audit, exactly like the arrangements OIG described. The absence of documentation is itself evidence that the fee compensated referrals rather than consulting.
Free-Product Programs Tied to Purchase Volume
A manufacturer that ships free skin substitute product and expects a return purchase once a patient's benefit resets has created remuneration under the AKS whether or not cash changes hands. OIG has approved narrow free-product arrangements in advisory opinions that carried specific safeguards: no product billed to a federal program, no volume expectation, and no tie between the free units and future orders. A program a manufacturer's sales team frames as building toward a purchase target lacks those safeguards, and it is the version OIG has repeatedly flagged as carrying substantial risk of federal program abuse.
How a Kickback Becomes False Claims Act Exposure
Congress closed the gap between the AKS and the False Claims Act in 2010. Under 42 U.S.C. § 1320a-7b(g), a claim for an item or service that resulted from an AKS violation is a false claim, independent of whether the wound care itself was medically necessary. In the Arizona wound graft case, the government's $309 million civil settlement rested on the kickback theory alone, with no separate showing that any individual graft was unnecessary. The same overlap reaches other wound care billing patterns, as our coverage of the government's FCA theories in skin substitute cases and how UPICs select wound care practices for audit lays out: a kickback-tainted claim, an unsupported debridement code, and a graft claim that fails the local coverage determination governing the product billed can each independently support a False Claims Act allegation. Our guide to LCD documentation requirements covers that third path in detail.
A claim resulting from an illegal kickback is a false claim under the False Claims Act even when the wound care itself was medically appropriate.
Why Early Legal Counsel Is Critical
It is critical that wound care providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry touching a manufacturer or distributor relationship. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions about the terms of a rebate or consulting arrangement, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends wound care providers against Anti-Kickback Statute and False Claims Act allegations arising from manufacturer and distributor relationships, from the first subpoena or civil investigative demand through negotiated resolution or trial. Our bench includes a former federal prosecutor and attorneys who have represented providers through OIG and DOJ inquiries into rebate structures, consulting agreements, and free-product programs. If your practice has a manufacturer or distributor relationship under government scrutiny, contact us today for a free consultation.
